EW Form 144 shows planned sale of 8,950 shares by Larry L. Wood

Rhea-AI Filing Summary

Edwards Lifesciences (EW) reported a Form 144 notice indicating that Larry L. Wood plans to sell 8,950 shares of common stock. The filing lists an aggregate market value of 653,522.00 and an approximate sale date of 10/16/2025. The broker is Charles Schwab & Co., Inc., and the shares are listed on the NYSE.

The shares to be sold were acquired on 10/16/2025 through an employee stock option exercise via a broker payment for cashless exercise. The filing also notes a prior sale in the past three months: 8,950 shares on 08/18/2025 for gross proceeds of 698,679.00. Shares outstanding are listed as 587,100,000; this is a baseline figure, not the amount being sold.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	8950	653522.00	587100000	10/16/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/16/2025	Employee Stock Option Exercise	EDWARDS LIFESCIENCES CORPORATION			8950	10/16/2025	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Larry L Wood ONE EDWARDS WAY IRVINE CA 92614	Edwards Lifesciences Corp	08/18/2025	8950	698679.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What did Edwards Lifesciences (EW) disclose in this Form 144?

A notice that Larry L. Wood plans to sell 8,950 shares of Edwards Lifesciences common stock.

What is the aggregate market value of the planned sale for EW?

The filing lists an aggregate market value of 653,522.00 for the planned sale.

When is the approximate sale date for the EW shares?

The approximate date of sale is 10/16/2025.

How were the EW shares to be sold acquired?

They were acquired on 10/16/2025 via an employee stock option exercise with broker payment for cashless exercise.

Which broker and exchange are associated with the EW sale?

Broker: Charles Schwab & Co., Inc.; Exchange: NYSE.

Were there recent sales by the same person for EW?

Yes. 8,950 shares were sold on 08/18/2025 for gross proceeds of 698,679.00.

How many EW shares are outstanding?

The filing lists 587,100,000 shares outstanding.